Ligands targeted to epidermal growth factor receptors and compositions for use in treating tumors

Patent metadata

Field	Value
Publication number	US-12527879-B2
Application number	US-202017616002-A
Country	US
Kind code	B2
Filing date	May 31, 2020
Priority date	Jun 4, 2019
Publication date	Jan 20, 2026
Grant date	Jan 20, 2026

Abstract

The present application relates to ligands targeted to epidermal growth factor receptor (EGFR) and compositions for use in treating tumors. Specifically, a ligand targeted to EGFR is disclosed. The ligand comprises a heavy chain variable domain and a light chain variable domain. The ligand may be selected from the group consisting of a single chain variable fragment, a fusion protein, a monoclonal antibody, and an antigen-binding fragment thereof. The ligand may be conjugated to a liposome or a nanoparticle that encapsulates at least one chemotherapeutic agent to form a ligand-targeted liposomal or nanoparticle drug. Also disclosed are conjugates and formulations for use in treating tumors such as squamous cell carcinoma of head and neck. A method for making a ligand-targeted liposomal drug is also disclosed. The drug may be a chemotherapeutic agent selected from the group consisting of doxorubicine and vinorelbine.

First claim

What is claimed is:

1 . A ligand targeting to epidermal growth factor receptor (EGFR), comprising:
(a) a heavy chain variable domain (V H ), comprising V H CDR1, V H CDR2, and V H CDR3, wherein the V H CDR1, V H CDR2 and V H CDR3 comprise the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively; and (b) a light chain variable domain (V L ), comprising V L CDR1, V L CDR2, and V L CDR3, wherein the V L CDR1, V L CDR2, and V L CDR3 comprise the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, respectively.

2 . The ligand of claim 1 , wherein the V H comprises the amino acid sequence of SEQ ID NO: 7 and the V L comprises the amino acid sequence of SEQ ID NO: 8.

3 . The ligand of claim 1 , which comprises the amino acid sequence of SEQ ID NO: 9.

4 . The ligand of claim 1 , further comprising a peptide linking the V H to the V L .

5 . The ligand of claim 1 , wherein the ligand is selected from the group consisting of a single chain variable fragment (scFv), a fusion protein, and a monoclonal antibody or an antigen-binding fragment thereof.

6 . A conjugate comprising:
(a) the ligand of claim 1 ; (b) a liposome, conjugated to the ligand.

7 . The conjugate of claim 6 , wherein the liposome is conjugated with polyethylene glycol (PEG) forming a PEGylated liposome.

8 . The conjugate of claim 7 , further comprising at least one chemotherapeutic agent encapsulated within the liposome.

9 . The conjugate of claim 8 , wherein the at least one chemotherapeutic compound is selected from the group consisting of doxorubicin and vinorelbine.

10 . A method for treating an EGFR-expressing tumor in a subject in need thereof, comprising:
administering to the subject in need thereof a therapeutically effective amount of the conjugate of claim 8 to treat the EGFR-expressing tumor in the subject in need thereof.

11 . A method for treating squamous cell carcinoma in a subject in need thereof, comprising:
administering to the subject in need thereof a therapeutically effective amount of the conjugate of claim 8 to treat the squamous cell carcinoma in the subject in need thereof.

12 . An expression vector, a phage, or a cell, comprising and/or expressing the ligand of claim 1 .

13 . The ligand of claim 1 , wherein the ligand is a scFv with the V H located at N-terminal to the V L and linked to the V L via a linker peptide.

14 . A method of making a ligand targeting liposomal drug, comprising:
(a) affording a PEGylated liposome; (b) encapsulating at least one chemotherapeutic agent within the PEGylated liposome to obtain a PEGylated liposomal drug; (c) reducing the ligand of claim 1 to obtain a reduced ligand; (d) inserting a PEGylation reagent with a 1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine (DSPE) phospholipid and a maleimide into the PEGylated liposomal drug to afford a maleimide-PEG-DSPE-inserting liposomal drug; (e) conjugating the reduced ligand to the maleimide-PEG-DSPE-inserting liposomal drug to obtain the ligand targeting liposomal drug.

15 . A conjugate comprising:
(a) the ligand of claim 2 ; (b) a liposome, conjugated to the ligand.

16 . A conjugate comprising:
(a) the ligand of claim 3 ; (b) a liposome, conjugated to the ligand.

17 . A conjugate comprising:
(a) the ligand of claim 4 ; (b) a liposome, conjugated to the ligand.

18 . A conjugate comprising:
(a) the ligand of claim 5 ; (b) a liposome, conjugated to the ligand.

19 . The conjugate of claim 18 , wherein the liposome is conjugated with polyethylene glycol (PEG) forming a PEGylated liposome.

20 . A method for treating a tumor in a subject in need thereof, comprising:
administering to the subject in need thereof a therapeutically effective amount of the conjugate of claim 9 to treat the tumor in the subject in need thereof, wherein the tumor is an EGFR-expressing tumor or squamous cell carcinoma.

Assignees

• Academia Sinica

Inventors

• Wu Han-Chung
• Wang Yi-Ping
• Liu I-Ju
• Chung Meng-Jhe

Classifications

• C07K2317/77

  Internalization into the cell · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title

• C07K16/286

  against neuromediator receptors, e.g. serotonin receptor, dopamine receptor · CPC title

• A61P35/00

  Antineoplastic agents · CPC title